Qu Zepeng, Liu Hongbin, Yang Ji, Zheng Linggang, Huang Jumin, Wang Ziming, Xie Chun, Zuo Wenlong, Xia Xiong, Sun Lin, Zhou Yifa, Xie Ying, Lu Jingguang, Zhu Yizhun, Yu Lili, Liu Lihua, Zhou Hua, Dai Lei, Leung Elaine Lai-Han
School of Pharmacy, Faculty of Medicine & State Key Laboratory of Quality Research in Chinese Medicines, Macau University of Science and Technology, Taipa, Macau, China.
CAS Key Laboratory of Quantitative Engineering Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China.
Nat Commun. 2025 Jan 14;16(1):638. doi: 10.1038/s41467-025-55845-7.
Human gut Bacteroides and Parabacteroides species play crucial roles in human health and are known for their capacity to utilize diverse polysaccharides. Understanding how these bacteria utilize medicinal polysaccharides is foundational for developing polysaccharides-based prebiotics and drugs. Here, we systematically mapped the utilization profiles of 20 different medicinal polysaccharides by 28 human gut Bacteroides and Parabacteroides species. The growth profiles exhibited substantial variation across different bacterial species and medicinal polysaccharides. Ginseng polysaccharides promoted the growth of multiple Bacteroides and Parabacteroides species; in contrast, Dendrobium polysaccharides selectively promoted the growth of Bacteroides uniformis. This distinct utilization profile was associated with genomic variation in carbohydrate-active enzymes, rather than monosaccharides composition variation among medicinal polysaccharides. Through comparative transcriptomics and genetical manipulation, we validated that the polysaccharide utilization locus PUL34_Bu enabled Bacteroides uniformis to utilize Dendrobium polysaccharides (i.e. glucomannan). In addition, we found that the GH26 enzyme in PUL34_Bu allowed Bacteroides uniformis to utilize multiple plant-derived mannan. Overall, our results revealed the selective utilization of medicinal polysaccharide by Bacteroides and Parabacteroides species and provided insights into the use of polysaccharides in engineering the human gut microbiome.
人类肠道中的拟杆菌属和副拟杆菌属物种对人类健康起着至关重要的作用,并且以其利用多种多糖的能力而闻名。了解这些细菌如何利用药用多糖是开发基于多糖的益生元和药物的基础。在此,我们系统地绘制了28种人类肠道拟杆菌属和副拟杆菌属物种对20种不同药用多糖的利用图谱。生长图谱显示不同细菌物种和药用多糖之间存在显著差异。人参多糖促进了多种拟杆菌属和副拟杆菌属物种的生长;相比之下,石斛多糖选择性地促进了单形拟杆菌的生长。这种独特的利用图谱与碳水化合物活性酶的基因组变异有关,而不是药用多糖之间的单糖组成变异。通过比较转录组学和基因操作,我们验证了多糖利用位点PUL34_Bu使单形拟杆菌能够利用石斛多糖(即葡甘露聚糖)。此外,我们发现PUL34_Bu中的GH26酶使单形拟杆菌能够利用多种植物来源的甘露聚糖。总体而言,我们的结果揭示了拟杆菌属和副拟杆菌属物种对药用多糖的选择性利用,并为利用多糖工程改造人类肠道微生物群提供了见解。